Developer docs
API playgroundTry for free, no card

Search company profiles

Cairn Diagnostics

Full company profile

uuid000hduh

Namestring
Cairn Diagnostics
Legal namestring
Advanced Breath Diagnostics, LLC
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Cairn Diagnostics, operating as Advanced Breath Diagnostics, LLC, is a privately held medical diagnostics company headquartered in Brentwood, Tennessee, that has developed and commercializes the 13C-Spirulina Gastric Emptying Breath Test (GEBT), the only FDA-approved breath test for diagnosing gastroparesis. The company's core technology uses pharmaceutical-grade Spirulina (blue-green algae) enriched with the non-radioactive stable isotope Carbon-13 as a substrate; after ingestion, breath samples are analyzed via gas isotope ratio mass spectrometry (GIRMS) in a CLIA-certified laboratory to measure the rate of solid-phase gastric emptying at six timepoints over a four-hour evaluation period. The test holds FDA Pre-Market Approval (PMA 110015, granted April 2015) and a PMA supplement (PMA 110015 S008, granted August 2021) for telehealth-based at-home administration, which Cairn has combined with direct-to-patient kit shipping and remote clinical supervision.

The company generates revenue under a transactional diagnostic services model billed under CPT code 91065, with Medicare coverage approved in July 2020 and an increasing share of commercial payers following. Its go-to-market operates through two complementary channels: a prescription-based provider ordering channel (physicians, nurse practitioners, and physician assistants order via fax or email, with kits shipped to patients) and a direct-to-consumer telehealth administration channel that eliminates the need for nuclear medicine facility visits. The addressable market is approximately 5 million US adults living with gastroparesis, and the test is recommended in ACG and AGA clinical guidelines. Cairn maintains ISO 13485:2016 certified facilities in Brentwood (headquarters, kit manufacturing, and CLIA lab) and Franklin (13C-Spirulina API production), and handles payer billing and appeals on behalf of provider practices. The company is founder-led, with Kerry Bush serving as President and COO, and operates with no disclosed external institutional funding, partnerships, or acquisitions.

Short descriptiontext

Cairn Diagnostics is a privately held Tennessee-based diagnostics company that provides the FDA-approved 13C-Spirulina Gastric Emptying Breath Test (GEBT) for diagnosing gastroparesis in adult patients, serving healthcare providers through prescription-based and telehealth-enabled at-home testing under CPT code 91065.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBrentwood, United States
HQ citystring
Brentwood
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
breath diagnostics, gastroparesis testing, gastric emptying tests, medical diagnostic services, at-home diagnostic testing
Industry1 code
PRIMARYHLAKAEAE
Motility & Functional GI Disorders
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Gastrointestinal Diagnostics
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Testing Services
TypeTransaction Fee
Description

Cairn Diagnostics generates revenue through providing the 13C-Spirulina Gastric Emptying Breath Test (GEBT) diagnostic service. Healthcare providers order the test for patients with suspected gastroparesis. The test kit is shipped to the patient's home, clinical administration is performed via telehealth or in-office, breath samples are analyzed in the CLIA-certified laboratory, and results are reported to the ordering provider. Billed under CPT code 91065.

cairndiagnostics.com
2Insurance and Medicare Billing
TypeSubscription Recurring
Description

GEBT is covered by Medicare (coverage approved July 2020) and an increasing number of commercial insurance payers. Cairn Diagnostics handles all billing and appeals on behalf of provider practices, working directly with payers to ensure smooth claims processing and providing transparent patient communication regarding coverage.

cairndiagnostics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1GEBT diagnostic test billed under CPT code 91065
ModelOtherBilling cadencePay-as-you-go
Notes

Medicare coverage approved July 2020. Cairn Diagnostics handles all billing and appeals, providing transparent communication with patients regarding coverage and potential costs. No prior authorization typically required.

cairndiagnostics.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Cairn Diagnostics provides the 13C-Spirulina Gastric Emptying Breath Test (GEBT), an FDA-approved, non-radioactive breath-based diagnostic test for gastroparesis. Healthcare providers order the test, a kit is shipped directly to the patient's home, breath samples are analyzed in a CLIA-certified laboratory using gas isotope ratio mass spectrometry, and results are reported back to the ordering provider. The company also operates a telehealth-enabled administration model allowing at-home completion of the 4-hour test under remote clinical supervision.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 73-97% agreement with gastric scintigraphy results
+3 more records
Product overview1 text field

Cairn Diagnostics offers the ¹³C-Spirulina Gastric Emptying Breath Test (GEBT) as its core diagnostic product—a single FDA-approved test for diagnosing gastroparesis. The GEBT can be administered either in a physician's office or via Cairn's telehealth administration service, where patients complete the 4-hour test at home under virtual supervision. The company's product portfolio centers on this one test, with complementary resources including a Breath Test Timer app for patient use. The GEBT kit is shipped directly to patients' homes, and breath samples are analyzed in Cairn's CLIA-certified laboratory with results delivered to ordering providers.

Product and service2 records
113C-Spirulina Gastric Emptying Breath Test (GEBT)
CategoryDiagnostic Test
Description

FDA-approved, non-radioactive breath test that measures the rate of solid-phase gastric emptying to aid in diagnosing gastroparesis in symptomatic adults. The patient consumes a pre-measured test meal containing 13C-Spirulina (pharmaceutical-grade Spirulina enriched with Carbon-13 stable isotope), and breath samples are collected at 6 timepoints over a 4-hour period. Samples are analyzed using gas isotope ratio mass spectrometry (GIRMS) in a CLIA-certified laboratory and reported using the kPCD metric. The test is prescribed and ordered by healthcare providers (physicians, NPs, PAs).

2GEBT Telehealth Administration Service
CategoryAdministration Service
Description

Remote virtual supervision and administration of the GEBT test via telehealth, allowing patients to complete the 4-hour test at home with real-time clinical support from Cairn's clinical team through scheduled video calls. Eliminates the need for in-person visits to a nuclear medicine facility and expands access to rural and underserved populations.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Exact Sciences is a major GI-focused diagnostics company with non-invasive colorectal cancer screening tests, sharing the gastroenterology channel and non-invasive testing theme but addressing a different indication.

TypeDirect peer
Description

Medtronic markets the SmartPill wireless motility capsule system, which directly competes with GEBT as a non-scintigraphy alternative for gastroparesis diagnosis in the same gastroenterology ordering workflow.

TypeBroad incumbent
Description

Labcorp is a national clinical laboratory operator offering a wide range of diagnostic testing services including GI panels; it overlaps with Cairn through lab-based diagnostic services but does not specialize in breath-based gastroparesis testing.

TypeEmerging player
Description

Anixa Biosciences has been developing breath-based diagnostic tests for cancer detection, sharing Cairn's breath-based testing modality and clinical laboratory business model while addressing a different clinical indication.

TypeBroad incumbent
Description

Quest Diagnostics operates a national CLIA-certified clinical laboratory network offering specialty GI diagnostics including gastric emptying scintigraphy; it competes as a broad incumbent diagnostic services provider rather than as a breath-test specialist.

TypeOthers
Description

Cambridge Isotope Laboratories manufactures stable isotope-labeled compounds including 13C substrates used in clinical breath tests, serving as an enabling supplier/peer in the 13C breath testing ecosystem that supports Cairn's substrate manufacturing.

TypeBroad incumbent
Description

Otsuka has historically developed and commercialized 13C-urea breath tests for H. pylori, sharing Cairn's 13C breath test technology foundation and gastroenterology channel while addressing a different indication.

TypeDirect peer
Description

Exalenz developed 13C-labeled urea breath tests for H. pylori and other 13C-based GI breath diagnostics, sharing Cairn's 13C stable isotope breath-test platform approach and overlapping gastroenterology customer base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights1 record

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cairn Diagnostics

Gastrointestinal Diagnosticscairndiagnostics.com

Cairn Diagnostics is a privately held Tennessee-based diagnostics company that provides the FDA-approved 13C-Spirulina Gastric Emptying Breath Test (GEBT) for diagnosing gastroparesis in adult patients, serving healthcare providers through prescription-based and telehealth-enabled at-home testing under CPT code 91065.

What Cairn Diagnostics does

Cairn Diagnostics, operating as Advanced Breath Diagnostics, LLC, is a privately held medical diagnostics company headquartered in Brentwood, Tennessee, that has developed and commercializes the 13C-Spirulina Gastric Emptying Breath Test (GEBT), the only FDA-approved breath test for diagnosing gastroparesis. The company's core technology uses pharmaceutical-grade Spirulina (blue-green algae) enriched with the non-radioactive stable isotope Carbon-13 as a substrate; after ingestion, breath samples are analyzed via gas isotope ratio mass spectrometry (GIRMS) in a CLIA-certified laboratory to measure the rate of solid-phase gastric emptying at six timepoints over a four-hour evaluation period. The test holds FDA Pre-Market Approval (PMA 110015, granted April 2015) and a PMA supplement (PMA 110015 S008, granted August 2021) for telehealth-based at-home administration, which Cairn has combined with direct-to-patient kit shipping and remote clinical supervision.

The company generates revenue under a transactional diagnostic services model billed under CPT code 91065, with Medicare coverage approved in July 2020 and an increasing share of commercial payers following. Its go-to-market operates through two complementary channels: a prescription-based provider ordering channel (physicians, nurse practitioners, and physician assistants order via fax or email, with kits shipped to patients) and a direct-to-consumer telehealth administration channel that eliminates the need for nuclear medicine facility visits. The addressable market is approximately 5 million US adults living with gastroparesis, and the test is recommended in ACG and AGA clinical guidelines. Cairn maintains ISO 13485:2016 certified facilities in Brentwood (headquarters, kit manufacturing, and CLIA lab) and Franklin (13C-Spirulina API production), and handles payer billing and appeals on behalf of provider practices. The company is founder-led, with Kerry Bush serving as President and COO, and operates with no disclosed external institutional funding, partnerships, or acquisitions.

Cairn Diagnostics firmographics

Firmographics
Name
Cairn Diagnostics
Legal name
Advanced Breath Diagnostics, LLC
Website
https://cairndiagnostics.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Cairn Diagnostics is a privately held Tennessee-based diagnostics company that provides the FDA-approved 13C-Spirulina Gastric Emptying Breath Test (GEBT) for diagnosing gastroparesis in adult patients, serving healthcare providers through prescription-based and telehealth-enabled at-home testing under CPT code 91065.
Ownership category
akta.pro rank

Cairn Diagnostics industry classification

Industry
Product category
Gastrointestinal Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAKAEAE
Motility & Functional GI Disorders

Keywords

  • Breath diagnostics
  • Gastroparesis testing
  • Gastric emptying tests
  • Medical diagnostic services
  • At-home diagnostic testing

Where Cairn Diagnostics is headquartered

Location

Headquarters

HQ city
Brentwood
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Cairn Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Testing Services: Cairn Diagnostics generates revenue through providing the 13C-Spirulina Gastric Emptying Breath Test (GEBT) diagnostic service. Healthcare providers order the test for patients with suspected gastroparesis. The test kit is shipped to the patient's home, clinical administration is performed via telehealth or in-office, breath samples are analyzed in the CLIA-certified laboratory, and results are reported to the ordering provider. Billed under CPT code 91065.
  2. Insurance and Medicare Billing: GEBT is covered by Medicare (coverage approved July 2020) and an increasing number of commercial insurance payers. Cairn Diagnostics handles all billing and appeals on behalf of provider practices, working directly with payers to ensure smooth claims processing and providing transparent patient communication regarding coverage.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goGEBT diagnostic test billed under CPT code 91065

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Cairn Diagnostics product offering

Product offering

Core offering

Cairn Diagnostics provides the 13C-Spirulina Gastric Emptying Breath Test (GEBT), an FDA-approved, non-radioactive breath-based diagnostic test for gastroparesis. Healthcare providers order the test, a kit is shipped directly to the patient's home, breath samples are analyzed in a CLIA-certified laboratory using gas isotope ratio mass spectrometry, and results are reported back to the ordering provider. The company also operates a telehealth-enabled administration model allowing at-home completion of the 4-hour test under remote clinical supervision.

Product overview

Cairn Diagnostics offers the ¹³C-Spirulina Gastric Emptying Breath Test (GEBT) as its core diagnostic product—a single FDA-approved test for diagnosing gastroparesis. The GEBT can be administered either in a physician's office or via Cairn's telehealth administration service, where patients complete the 4-hour test at home under virtual supervision. The company's product portfolio centers on this one test, with complementary resources including a Breath Test Timer app for patient use. The GEBT kit is shipped directly to patients' homes, and breath samples are analyzed in Cairn's CLIA-certified laboratory with results delivered to ordering providers.

Differentiator

Problem solved

Functional benefit

Products and services

  • 13C-Spirulina Gastric Emptying Breath Test (GEBT) FDA-approved, non-radioactive breath test that measures the rate of solid-phase gastric emptying to aid in diagnosing gastroparesis in symptomatic adults. The patient consumes a pre-measured test meal containing 13C-Spirulina (pharmaceutical-grade Spirulina enriched with Carbon-13 stable isotope), and breath samples are collected at 6 timepoints over a 4-hour period. Samples are analyzed using gas isotope ratio mass spectrometry (GIRMS) in a CLIA-certified laboratory and reported using the kPCD metric. The test is prescribed and ordered by healthcare providers (physicians, NPs, PAs).
  • GEBT Telehealth Administration Service Remote virtual supervision and administration of the GEBT test via telehealth, allowing patients to complete the 4-hour test at home with real-time clinical support from Cairn's clinical team through scheduled video calls. Eliminates the need for in-person visits to a nuclear medicine facility and expands access to rural and underserved populations.

Quantifiable outcome

  • 73-97% agreement with gastric scintigraphy results
  • +3 more outcomes

Companies that use Cairn Diagnostics

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Cairn Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Cairn Diagnostics partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Cairn Diagnostics competitors and assessment

Company assessment

Broad incumbents

  • Exact Sciences: Exact Sciences is a major GI-focused diagnostics company with non-invasive colorectal cancer screening tests, sharing the gastroenterology channel and non-invasive testing theme but addressing a different indication.
  • Laboratory Corporation of America (Labcorp): Labcorp is a national clinical laboratory operator offering a wide range of diagnostic testing services including GI panels; it overlaps with Cairn through lab-based diagnostic services but does not specialize in breath-based gastroparesis testing.
  • Quest Diagnostics: Quest Diagnostics operates a national CLIA-certified clinical laboratory network offering specialty GI diagnostics including gastric emptying scintigraphy; it competes as a broad incumbent diagnostic services provider rather than as a breath-test specialist.
  • Otsuka Holdings: Otsuka has historically developed and commercialized 13C-urea breath tests for H. pylori, sharing Cairn's 13C breath test technology foundation and gastroenterology channel while addressing a different indication.

Direct peers

  • Medtronic: Medtronic markets the SmartPill wireless motility capsule system, which directly competes with GEBT as a non-scintigraphy alternative for gastroparesis diagnosis in the same gastroenterology ordering workflow.
  • Exalenz Bioscience (Meridian Bioscience): Exalenz developed 13C-labeled urea breath tests for H. pylori and other 13C-based GI breath diagnostics, sharing Cairn's 13C stable isotope breath-test platform approach and overlapping gastroenterology customer base.

Emerging players

  • Anixa Biosciences: Anixa Biosciences has been developing breath-based diagnostic tests for cancer detection, sharing Cairn's breath-based testing modality and clinical laboratory business model while addressing a different clinical indication.

Others

  • Cambridge Isotope Laboratories: Cambridge Isotope Laboratories manufactures stable isotope-labeled compounds including 13C substrates used in clinical breath tests, serving as an enabling supplier/peer in the 13C breath testing ecosystem that supports Cairn's substrate manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights1 record

Customer concentration

Cairn Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cairn Diagnostics leadership team

Management profile

Number of profiles

Profiles4 records

Cairn Diagnostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cairn Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cairn Diagnostics

What does Cairn Diagnostics do?

Cairn Diagnostics provides the 13C-Spirulina Gastric Emptying Breath Test (GEBT), an FDA-approved, non-radioactive breath-based diagnostic test for gastroparesis. Healthcare providers order the test, a kit is shipped directly to the patient's home, breath samples are analyzed in a CLIA-certified laboratory using gas isotope ratio mass spectrometry, and results are reported back to the ordering provider. The company also operates a telehealth-enabled administration model allowing at-home completion of the 4-hour test under remote clinical supervision.

Is Cairn Diagnostics a public or private company?

Cairn Diagnostics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Cairn Diagnostics founded?

Cairn Diagnostics was founded in 2015. It employs 11 to 50 people.

Where is Cairn Diagnostics based?

Cairn Diagnostics is headquartered in Brentwood, United States, in the North America region.

How does Cairn Diagnostics make money?

Two revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are insurance and Medicare Billing.

Who are Cairn Diagnostics's main competitors?

Broad incumbents on record are Exact Sciences, Laboratory Corporation of America (Labcorp), Quest Diagnostics and Otsuka Holdings. Direct peers are Medtronic and Exalenz Bioscience (Meridian Bioscience). Anixa Biosciences is listed as an emerging player. Cambridge Isotope Laboratories is listed as an others.

Does Cairn Diagnostics have an API?

No public API is recorded for Cairn Diagnostics.

What industry is Cairn Diagnostics in?

Cairn Diagnostics's product category is Gastrointestinal Diagnostics. Its primary akta.pro industry code is HLAKAEAE, Motility & Functional GI Disorders. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals